Biohaven BHVN 深 沪
交易中 10-06 11:18:33 美东时间
12.53
-0.460
-3.54%
华盛通- 最 高18.24
- 今 开13.00
- 成交量 47.64万股
- 最 低 11.93
- 昨 收 12.99
- 总市值 89.02万
- 52周最高 18.5657
- 市盈率 静 --
- 换手率 670.60%
- 52周最低 7.48
- 委 比 -39.36%
- 总股本 7.10万
- 历史最高 152.56
- 量 比 2.25
- 振 幅 48.58%
- 历史最低 7.10
- 每 手 1
- 风险率 2.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.
06-30 02:04
Biohaven Initiates First-In-Human Dosing For BHV-8100 Pyruvate Kinase M2 Isoform Modulator
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies for rare and common diseases, today
06-01 19:31
Biohaven Presents New Data From Kv7.2/7.3 Channel Activator Program To Treat Focal Epilepsy
Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases,
05-26 19:38
Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why
Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million private placement announcement.
03-19 15:11
US Stocks Mixed; Biohaven Shares Fall
U.S. stocks traded mixed this morning, with the Dow Jones index falling around ...
2025-12-26 22:45
Biohaven Misses The Mark In Depression Trial, Stock Falls
Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depressive symptoms in comparison to placebo.
2025-12-26 21:20
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday
US stock futures slightly lower. Stocks to watch: NVIDIA, Dynavax, Sobr Safe, Davis Commodities, Biohaven.
2025-12-26 16:19
What Caused Biohaven (BHVN) Shares To Drop More Than 16% After Hours?
Biohaven shares fell 16.19% in after-hours trading Wednesday after its Phase 2 depression drug trial missed the primary endpoint.
2025-12-25 14:52
Biohaven Announces $150M Common Stock Offering
Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases,
2025-11-12 05:06
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade.
2025-11-06 01:53
